Literature DB >> 24685152

Proton therapy expansion under current United States reimbursement models.

John Kerstiens1, Peter A S Johnstone2.   

Abstract

PURPOSE: To determine whether all the existing and planned proton beam therapy (PBT) centers in the United States can survive on a local patient mix that is dictated by insurers, not by number of patients. METHODS AND MATERIALS: We determined current and projected cancer rates for 10 major US metropolitan areas. Using published utilization rates, we calculated patient percentages who are candidates for PBT. Then, on the basis of current published insurer coverage policies, we applied our experience of what would be covered to determine the net number of patients for whom reimbursement is expected. Having determined the net number of covered patients, we applied our average beam delivery times to determine the total number of minutes needed to treat that patient over the course of their treatment. We then calculated our expected annual patient capacity per treatment room to determine the appropriate number of treatment rooms for the area.
RESULTS: The population of patients who will be both PBT candidates and will have treatments reimbursed by insurance is significantly smaller than the population who should receive PBT. Coverage decisions made by insurers reduce the number of PBT rooms that are economically viable.
CONCLUSIONS: The expansion of PBT centers in the US is not sustainable under the current reimbursement model. Viability of new centers will be limited to those operating in larger regional metropolitan areas, and few metropolitan areas in the US can support multiple centers. In general, 1-room centers require captive (non-PBT-served) populations of approximately 1,000,000 lives to be economically viable, and a large center will require a population of >4,000,000 lives. In areas with smaller populations or where or a PBT center already exists, new centers require subsidy.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24685152     DOI: 10.1016/j.ijrobp.2014.02.014

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma.

Authors:  Christopher R Peeler; Dragan Mirkovic; Uwe Titt; Pierre Blanchard; Jillian R Gunther; Anita Mahajan; Radhe Mohan; David R Grosshans
Journal:  Radiother Oncol       Date:  2016-11-16       Impact factor: 6.280

2.  Strategic level proton therapy patient admission planning: a Markov decision process modeling approach.

Authors:  Ridvan Gedik; Shengfan Zhang; Chase Rainwater
Journal:  Health Care Manag Sci       Date:  2016-01-25

3.  Recommendations for the referral of patients for proton-beam therapy, an Alberta Health Services report: a model for Canada?

Authors:  S Patel; X Kostaras; M Parliament; I A Olivotto; R Nordal; K Aronyk; N Hagen
Journal:  Curr Oncol       Date:  2014-10       Impact factor: 3.677

4.  Variations in Proton Therapy Coverage in the State of Texas: Defining Medical Necessity for a Safe and Effective Treatment.

Authors:  Nikhil G Thaker; Ankit Agarwal; Matthew Palmer; Rosemarie Hontiveros; Stephen M Hahn; Bruce D Minsky; Ronald Walters; John Bingham; Thomas W Feeley; Thomas A Buchholz; Steven J Frank
Journal:  Int J Part Ther       Date:  2016-03-24

5.  A 20-Year Analysis of Clinical Trials Involving Proton Beam Therapy.

Authors:  Bismarck C L Odei; Dustin Boothe; Sameer R Keole; Carlos E Vargas; Robert L Foote; Steven E Schild; Jonathan B Ashman
Journal:  Int J Part Ther       Date:  2017-03-14

Review 6.  Proton beam therapy: clinical utility and current status in prostate cancer.

Authors:  Kosj Yamoah; Peter As Johnstone
Journal:  Onco Targets Ther       Date:  2016-09-16       Impact factor: 4.147

7.  Early Experience of the First Single-Room Gantry Mounted Active Scanning Proton Therapy System at an Integrated Cancer Center.

Authors:  Matthew K Forsthoefel; Elizabeth Ballew; Keith R Unger; Peter H Ahn; Sonali Rudra; Dalong Pang; Sean P Collins; Anatoly Dritschilo; William Harter; Nitika Paudel; Brian T Collins; Jonathan W Lischalk
Journal:  Front Oncol       Date:  2020-05-29       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.